Under the current situation of the rapid development of brain-like artificial intelligence and the increasingly complex electromagnetic environment, the most bionic and anti-interference spiking neural network has shown great potential in computing speed, real-time information processing, and spatiotemporal data processing. Spiking neural network is the core part of brain-like artificial intelligence, which realizes brain-like computing by simulating the structure of biological neural network and the way of information transmission. This article first summarizes the advantages and disadvantages of the five models, and analyzes the characteristics of several network topologies. Then, it summarizes the spiking neural network algorithms. The unsupervised learning based on spike timing dependent plasticity (STDP) rules and four types of supervised learning algorithms are analyzed. Finally, the research on brain-like neuromorphic chips at home and abroad are reviewed. This paper aims to provide learning ideas and research directions for new colleagues in the field of spiking neural network.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927433 | PMC |
http://dx.doi.org/10.7507/1001-5515.202011005 | DOI Listing |
Alzheimers Dement
December 2024
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Background: The prohibitive costs of drug development for Alzheimer's Disease (AD) emphasize the need for alternative in silico drug repositioning strategies. Graph learning algorithms, capable of learning intrinsic features from complex network structures, can leverage existing databases of biological interactions to improve predictions in drug efficacy. We developed a novel machine learning framework, the PreSiBOGNN, that integrates muti-modal information to predict cognitive improvement at the subject level for precision medicine in AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, DF, Mexico.
Background: The World Health Organization forecasts a population of 2,000 million people over 60 years by the year 2050, with 7% of this population suffering from dementia. Making a constant clinical-technological evaluation of older adults allows early detection of the disease and provides a better quality of life for the patient. In this sense, the research and development of innovative technological systems for the early detection of the disease, its monitoring and management of the growing number of patients with cognitive diseases has increased in recent years, integrating data collection and its automatic processing based on geriatric metrics into these systems using artificial intelligence (AI) methods.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Dementia poses a significant global crisis, yet 60% of cases go undetected, particularly among specific sub-populations. Timely diagnosis is crucial for implementing early intervention strategies. Challenges of current screening tools (e.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
National University, Muscat, Muscat, Oman.
Background: This study explores Alzheimer's prediction through brain MRI images, utilizing Convolutional Neural Networks (CNNs) and Lime interpretability. Based on an extensive ADNI MRI dataset, we demonstrate promising results in predicting Alzheimer's disease. Local Interpretable Model Agnostic Explanations (LIME) shed light on decision-making processes, enhancing transparency.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Medical University of South Carolina, Charleston, SC, USA.
Background: Repetitive transcranial magnetic stimulation enhances cognition in people with mild cognitive impairment (MCI). Whereas conventional treatment requires daily sessions for 4-6 weeks, accelerated intermittent theta burst stimulation (iTBS) shortens the treatment course to just 3 days, substantially improving feasibility of use in people with MCI. We conducted a Phase I safety and feasibility trial of iTBS in MCI, finding preliminary evidence of cognitive improvement.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!